Q-omics provides the consensus-scored MIR1272 profile across patient tissues and cancer cell-line models. MIR1272 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR1272 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR1272 RNA expression shows 6,453 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, and STAD as cancer lineages where MIR1272 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1272 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1272 survival associations across molecular data types. MIR1272 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1272 RNA expression–survival associations across cancer types. High MIR1272 expression shows unfavorable associations in UCEC, MESO, COAD, UVM, UCS and DLBC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR1272 RNA expression.
This table summarizes MIR1272 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1272. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1272 shows lower tumor expression in STAD and KIRP. The STAD box plot shows higher MIR1272 RNA expression in normal versus tumor tissue (log2 FC = −0.265, t-test p = .046).
This table shows molecular features associated with MIR1272 in patient tissues and cancer cell lines. In patient samples, MIR1272 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
